Vaccines
Vaccines, as with all products regulated by FDA, undergo a rigorous review of laboratory and clinical data to ensure the safety, efficacy, purity and potency of these products. Vaccines approved for marketing may also be required to undergo additional studies to further evaluate the vaccine and often to address specific questions about the vaccine's safety, effectiveness or possible side effects. The Center for Biologics Evaluation and Research (CBER) regulates vaccine products. Many of these are childhood vaccines that have contributed to a significant reduction of vaccine-preventable diseases.
Featured Products
Best Practices in Quality and Compliance Management
Price: $70.00
Price: $70.00
Immunogenicity To Biologics: Processes, Impact On Efficacy And Safety, and Management Strategy
Processes and effects of immunogenicity to biologics - screening methodologies - regulatory mandates - commercial repercussions of unwanted immune responses
Processes and effects of immunogenicity to biologics - screening methodologies - regulatory mandates - commercial repercussions of unwanted immune responses
Differences in GMP Requirements between Drugs and Biologics
Biologics regulations - drug regulations - differences in GMP requirements
Biologics regulations - drug regulations - differences in GMP requirements
Quality Expectations for Drugs and Biologics during Early Development: Phase 2
Phase 2 FDA Guidance Documents - QC studies - CMC quality elements - Common Technical Document CTD - Biologics License Application BLA - New Drug Application NDA
Phase 2 FDA Guidance Documents - QC studies - CMC quality elements - Common Technical Document CTD - Biologics License Application BLA - New Drug Application NDA